CD19 and cancer: The efficacy of CAR T cells, and recently CAR NK cells, has been shown for liquid tumors, most prominently in CD19+ lymphoid-derived cancers and several clinical studies currently explore the translation of these promising results to solid tumors (link to these studies on clinicaltrials.gov).